{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:06:45Z","timestamp":1792602405494,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01858-4","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T09:02:22Z","timestamp":1728291742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Post-marketing safety concerns with rimegepant based on a pharmacovigilance study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jia-Ling","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"1858_CR1","doi-asserted-by":"publisher","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders 3rd edn. Cephalalgia 38(1): 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"1858_CR2","doi-asserted-by":"publisher","unstructured":"GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Global Health Metrics 390(10100): 1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","DOI":"10.1016\/S0140-6736(17)32154-2"},{"issue":"12","key":"1858_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/brainsci12121612","volume":"12","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sciences 12(12): 1612.\u00a0https:\/\/doi.org\/10.3390\/brainsci12121612","journal-title":"Brain Sci"},{"key":"1858_CR4","doi-asserted-by":"publisher","unstructured":"Chiang CC, Schwedt TJ (2020) Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine\u2014The monoclonal antibodies and gepants. Progress in Brain Research 143\u2013170. https:\/\/doi.org\/10.1016\/bs.pbr.2020.06.019","DOI":"10.1016\/bs.pbr.2020.06.019"},{"key":"1858_CR5","doi-asserted-by":"publisher","unstructured":"Reuter U, Goadsby PJ, et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161). https:\/\/doi.org\/10.1016\/S0140-6736(18)32534-0","DOI":"10.1016\/S0140-6736(18)32534-0"},{"issue":"3","key":"1858_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","volume":"37","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023) Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs 37(3):255\u2013265. https:\/\/doi.org\/10.1007\/s40263-023-00988-8","journal-title":"CNS Drugs"},{"issue":"2","key":"1858_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton R B, Croop R, Stock EG et al (2019) Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine. New England Journal of Medicine 381(2):142\u2013149.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"1858_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3389\/fphar.2019.00795","volume":"10","author":"F Xu","year":"2019","unstructured":"Xu F, Sun W (2019) Network meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine. Front Pharmacol 10:795. https:\/\/doi.org\/10.3389\/fphar.2019.00795","journal-title":"Front Pharmacol"},{"key":"1858_CR9","doi-asserted-by":"publisher","unstructured":"Cao B, Gu S, Shen Z et al (2023) Evaluating ubrogepant-related adverse events using the FDA adverse event reporting system. Expert Opinion on Drug Safety 1\u20137. https:\/\/doi.org\/10.1080\/14740338.2023.2251390","DOI":"10.1080\/14740338.2023.2251390"},{"key":"1858_CR10","doi-asserted-by":"publisher","unstructured":"Bigal M, Rapoport A et al (2007) Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 47(4). https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00752","DOI":"10.1111\/j.1526-4610.2007.00752"},{"key":"1858_CR11","doi-asserted-by":"publisher","unstructured":"G\u00e9rard AO, Merino D, Van Obberghen EK et al (2022) Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. The Journal of Headache and Pain 23(1):53. https:\/\/doi.org\/10.1186\/s10194-022-01424-w","DOI":"10.1186\/s10194-022-01424-w"},{"issue":"12","key":"1858_CR12","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics12121180","volume":"12","author":"D Szkutnik-Fiedler","year":"2020","unstructured":"Szkutnik-Fiedler D (2020) Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics 12(12): 1180.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics12121180","journal-title":"Pharmaceutics"},{"key":"1858_CR13","doi-asserted-by":"publisher","unstructured":"Berger AA, Winnick A et al (2022) Rimegepant for the treatment of migraine. Health Psychology Research 10(5). https:\/\/doi.org\/10.52965\/001c.38534","DOI":"10.52965\/001c.38534"},{"issue":"8","key":"1858_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14656566.2023.2201375","volume":"24","author":"J Tajti","year":"2023","unstructured":"Tajti J, Szok D et al (2023) The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opin Pharmacother 24(8):947\u2013958. https:\/\/doi.org\/10.1080\/14656566.2023.2201375","journal-title":"Expert Opin Pharmacother"},{"key":"1858_CR15","doi-asserted-by":"publisher","unstructured":"Battini V, Carnovale C et al (2023) Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the food and drug administration adverse event reporting System. Expert Opinion on Drug Safety 1\u20138. https:\/\/doi.org\/10.1080\/14740338.2023.2223958","DOI":"10.1080\/14740338.2023.2223958"},{"key":"1858_CR16","doi-asserted-by":"publisher","unstructured":"Porreca F, Navratilova E et al (2024) Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia: Int J Headache 44(3). https:\/\/doi.org\/10.1177\/03331024241238153","DOI":"10.1177\/03331024241238153"},{"key":"1858_CR17","doi-asserted-by":"publisher","unstructured":"Jiang C, Qian J et al (2024) Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety. Pharmacology research & perspectives 12(1). https:\/\/doi.org\/10.1002\/prp2.1161","DOI":"10.1002\/prp2.1161"},{"key":"1858_CR18","doi-asserted-by":"publisher","unstructured":"Qi Y, Li J et al (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. Scientific reports 14(1). https:\/\/doi.org\/10.1038\/s41598-024-62356-w","DOI":"10.1038\/s41598-024-62356-w"},{"key":"1858_CR19","doi-asserted-by":"publisher","first-page":"204209862412580","DOI":"10.1177\/20420986241258049","volume":"15","author":"C Jiang","year":"2024","unstructured":"Jiang C, Zheng X et al (2024) A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime. Therapeutic Adv Drug Saf 15:20420986241258049.\u00a0https:\/\/doi.org\/10.1177\/20420986241258049","journal-title":"Therapeutic Adv Drug Saf"},{"key":"1858_CR20","doi-asserted-by":"publisher","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","volume":"15","author":"MT Wen","year":"2024","unstructured":"Wen MT, Li JC et al (2024) Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1391356. https:\/\/doi.org\/10.3389\/fphar.2024.1391356","journal-title":"Front Pharmacol"},{"key":"1858_CR21","doi-asserted-by":"publisher","unstructured":"Altebainawi AF, Alfaraj LA et al (2023) Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Therapeutic Adv drug Saf 14. https:\/\/doi.org\/10.1177\/20420986231154075","DOI":"10.1177\/20420986231154075"},{"key":"1858_CR22","doi-asserted-by":"publisher","unstructured":"Song Y, Xu YL et al (2020) Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 Years. Oncology Research and Treatment 43(3). https:\/\/doi.org\/10.1159\/000505376","DOI":"10.1159\/000505376"},{"key":"1858_CR23","doi-asserted-by":"publisher","unstructured":"Guo M, Shu Y et al (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep 12(1). https:\/\/doi.org\/10.1038\/s41598-022-23726-4","DOI":"10.1038\/s41598-022-23726-4"},{"issue":"1","key":"1858_CR24","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y et al (2022) A real-world pharmacovigilance study of FDA adverse event reporting System (FAERS) events for osimertinib. Sci Rep 12(1):19555. https:\/\/doi.org\/10.1038\/s41598-022-23834-1","journal-title":"Sci Rep"},{"key":"1858_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.18433\/jpps33020","volume":"25","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dong C et al (2022) Post-marketing safety of vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting System. J Pharm Pharm Sci 25:377\u2013390. https:\/\/doi.org\/10.18433\/jpps33020","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"1858_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s10194-024-01832-0","volume":"25","author":"Zfeng Chen","year":"2024","unstructured":"Chen Zfeng, Kong X et al (2024) Global, regional, and national burden and trends of migraine among youths and young adults aged 15\u201339 years from 1990 to 2021: findings from the global burden of disease study 2021. J Headache Pain 25(1):131. https:\/\/doi.org\/10.1186\/s10194-024-01832-0","journal-title":"J Headache Pain"},{"issue":"8","key":"1858_CR27","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R et al (2020) Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache 60(8):1734\u20131742. https:\/\/doi.org\/10.1111\/head.13930","journal-title":"Headache"},{"issue":"1","key":"1858_CR28","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.1038\/s41598-024-57909-y","volume":"14","author":"F Huang","year":"2024","unstructured":"Huang F, San X et al (2024) Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database. Sci Rep 14(1):7489. https:\/\/doi.org\/10.1038\/s41598-024-57909-y","journal-title":"Sci Rep"},{"issue":"10","key":"1858_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000201630","volume":"100","author":"S Louis","year":"2023","unstructured":"Louis S, Carlson AK et al (2023) Impacts of climate change and air pollution on neurologic health, Disease, and practice: a scoping review. Neurology 100(10):474\u2013483. https:\/\/doi.org\/10.1212\/WNL.0000000000201630","journal-title":"Neurology"},{"issue":"2","key":"1858_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.7150\/ijbs.88370","volume":"20","author":"S Khan","year":"2024","unstructured":"Khan S, Siddique R et al (2024) Towards improving the prognosis of stroke through targeting the circadian clock system. Int J Biol Sci 20(2):403\u2013413. https:\/\/doi.org\/10.7150\/ijbs.88370","journal-title":"Int J Biol Sci"},{"key":"1858_CR31","doi-asserted-by":"publisher","unstructured":"Bugge NS, Vetvik KG et al (2024) Cumulative exposure to estrogen may increase the risk of migraine in women. Cephalalgia: Int J Headache 44(1). https:\/\/doi.org\/10.1177\/03331024231225972","DOI":"10.1177\/03331024231225972"},{"key":"1858_CR32","doi-asserted-by":"publisher","unstructured":"Liu Y, Li H et al (2024) A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database. Front Pharmacol 15. https:\/\/doi.org\/10.3389\/fphar.2024.1368244","DOI":"10.3389\/fphar.2024.1368244"},{"key":"1858_CR33","doi-asserted-by":"publisher","unstructured":"Chen C, Ding L et al (2023) Updated insights on dementia-related risk of sacubitril\/valsartan: a real-world pharmacovigilance analysis. CNS Neurosci Ther 29(9). https:\/\/doi.org\/10.1111\/cns.14195","DOI":"10.1111\/cns.14195"},{"issue":"7","key":"1858_CR34","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Rimegepant First Approval. Drugs 80(7):741\u2013746. https:\/\/doi.org\/10.1007\/s40265-020-01301-3","journal-title":"Drugs"},{"issue":"1","key":"1858_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14740338.2023.2177270","volume":"22","author":"G Dong","year":"2023","unstructured":"Dong G, Kj\u00e6rgaard NA et al (2023) Ubrogepant and Rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Exp Opin Drug Saf 22(1):59\u201370. https:\/\/doi.org\/10.1080\/14740338.2023.2177270","journal-title":"Exp Opin Drug Saf"},{"issue":"9","key":"1858_CR36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/14740338.2022.2049231","volume":"21","author":"D Liang","year":"2022","unstructured":"Liang D, Sessa M (2022) Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Exp Opin Drug Saf 21(9):1205\u20131210. https:\/\/doi.org\/10.1080\/14740338.2022.2049231","journal-title":"Exp Opin Drug Saf"},{"key":"1858_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-023-01276-z","author":"S Jinesh","year":"2023","unstructured":"Jinesh S (2023) Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-023-01276-z","journal-title":"Inflammopharmacology"},{"key":"1858_CR38","doi-asserted-by":"publisher","unstructured":"Ak C, Yy L (2018) Neurophysiological symptoms and aspartame: What is the connection? Nutritional neuroscience 21(5). https:\/\/doi.org\/10.1080\/1028415X.2017.1288340","DOI":"10.1080\/1028415X.2017.1288340"},{"key":"1858_CR39","doi-asserted-by":"publisher","unstructured":"Rainsford KD (2013) Ibuprofen: from invention to an OTC therapeutic mainstay. Int J Clin Pract Suppl (178):9\u201320. https:\/\/doi.org\/10.1111\/ijcp.12055","DOI":"10.1111\/ijcp.12055"},{"key":"1858_CR40","doi-asserted-by":"publisher","unstructured":"Bjarnason I (2013) Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract Suppl (178):37\u201342. https:\/\/doi.org\/10.1111\/ijcp.12048","DOI":"10.1111\/ijcp.12048"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01858-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01858-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T19:02:18Z","timestamp":1728327738000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01858-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1858"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01858-4","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no trackable personal patient or reporter information from the FAERS database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}